121 related articles for article (PubMed ID: 32960816)
1. Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.
Chen Z; Li S; Mo J; Hawley E; Wang Y; He Y; Brosseau JP; Shipman T; Clapp DW; Carroll TJ; Le LQ
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32960816
[TBL] [Abstract][Full Text] [Related]
2. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas.
Oh JE; Ohta T; Satomi K; Foll M; Durand G; McKay J; Le Calvez-Kelm F; Mittelbronn M; Brokinkel B; Paulus W; Ohgaki H
J Neuropathol Exp Neurol; 2015 Oct; 74(10):952-9. PubMed ID: 26360373
[TBL] [Abstract][Full Text] [Related]
4. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancer.
Mota MSV; Jackson WP; Bailey SK; Vayalil P; Landar A; Rostas JW; Mulekar MS; Samant RS; Shevde LA
Carcinogenesis; 2018 Sep; 39(9):1165-1175. PubMed ID: 29893810
[TBL] [Abstract][Full Text] [Related]
6. Hippo Signaling Circuit and Divergent Tissue Growth in Mammalian Eye.
Moon KH; Kim JW
Mol Cells; 2018 Apr; 41(4):257-263. PubMed ID: 29665674
[TBL] [Abstract][Full Text] [Related]
7. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Mansouri S; Suppiah S; Mamatjan Y; Paganini I; Liu JC; Karimi S; Patil V; Nassiri F; Singh O; Sundaravadanam Y; Rath P; Sestini R; Gensini F; Agnihotri S; Blakeley J; Ostrow K; Largaespada D; Plotkin SR; Stemmer-Rachamimov A; Ferrer MM; Pugh TJ; Aldape KD; Papi L; Zadeh G
Acta Neuropathol; 2021 Jan; 141(1):101-116. PubMed ID: 33025139
[TBL] [Abstract][Full Text] [Related]
8. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins.
Mo J; Anastasaki C; Chen Z; Shipman T; Papke J; Yin K; Gutmann DH; Le LQ
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33108355
[TBL] [Abstract][Full Text] [Related]
9. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1 Promotes Ubiquitination and Degradation of NR4A3 via Direct Interaction Driven by ROS in Vascular Endothelial Cell Injury.
Lu B; Zhu Z; Sheng L; Li Y; Yang Y; Chen Y; Xue D; Zhou Y; Cai W; Chen C; Wei C; Xu D; Yan M; Lin S; Yan G; Yin W
Oxid Med Cell Longev; 2020; 2020():2048210. PubMed ID: 33163142
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
Zhao YY; Jia J; Zhang JJ; Xun YP; Xie SJ; Liang JF; Guo HG; Zhu JZ; Ma SL; Zhang SR
Acta Pharmacol Sin; 2021 Aug; 42(8):1288-1297. PubMed ID: 33159174
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.
Gillies TE; Pargett M; Silva JM; Teragawa CK; McCormick F; Albeck JG
Mol Syst Biol; 2020 Oct; 16(10):e9518. PubMed ID: 33073539
[TBL] [Abstract][Full Text] [Related]
13. NEDD4L-mediated Merlin ubiquitination facilitates Hippo pathway activation.
Wei Y; Yee PP; Liu Z; Zhang L; Guo H; Zheng H; Anderson B; Gulley M; Li W
EMBO Rep; 2020 Dec; 21(12):e50642. PubMed ID: 33058421
[TBL] [Abstract][Full Text] [Related]
14. Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.
Pham TH; Hagenbeek TJ; Lee HJ; Li J; Rose CM; Lin E; Yu M; Martin SE; Piskol R; Lacap JA; Sampath D; Pham VC; Modrusan Z; Lill JR; Klijn C; Malek S; Chang MT; Dey A
Cancer Discov; 2021 Mar; 11(3):778-793. PubMed ID: 33208393
[TBL] [Abstract][Full Text] [Related]
15. Control of skeletal morphogenesis by the Hippo-YAP/TAZ pathway.
Vanyai HK; Prin F; Guillermin O; Marzook B; Boeing S; Howson A; Saunders RE; Snoeks T; Howell M; Mohun TJ; Thompson B
Development; 2020 Nov; 147(21):. PubMed ID: 32994166
[TBL] [Abstract][Full Text] [Related]
16. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract][Full Text] [Related]
17. RAB11A-mediated YAP localization to adherens and tight junctions is essential for colonic epithelial integrity.
Goswami S; Balasubramanian I; D'Agostino L; Bandyopadhyay S; Patel R; Avasthi S; Yu S; Goldenring JR; Bonder EM; Gao N
J Biol Chem; 2021 Jul; 297(1):100848. PubMed ID: 34058200
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
19. High-throughput RNA sequencing identifies the miRNA expression profile, target genes, and molecular pathways contributing to growth of sporadic vestibular schwannomas.
Litwiniuk-Kosmala M; Makuszewska M; Niemczyk K; Bartoszewicz R; Wojtas B; Gielniewski B
Acta Neurochir (Wien); 2024 Feb; 166(1):71. PubMed ID: 38329606
[TBL] [Abstract][Full Text] [Related]
20. Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor.
Ivanisevic T; Steklov M; Lechat B; Cawthorne C; Gsell W; Velde GV; Deroose C; Van Laere K; Himmelreich U; Sewduth RN; Sablina AA
Cancer Commun (Lond); 2023 Dec; 43(12):1386-1390. PubMed ID: 37890861
[No Abstract] [Full Text] [Related]
[Next] [New Search]
